Mildronate as a regulator of protein expression in a rat model of Parkinson's disease.

BACKGROUND Mildronate (3-[2,2,2-trimethylhydrazinium] propionate dihydrate) traditionally is a well-known cardioprotective drug. However, our recent studies convincingly demonstrated its neuroprotective properties. The aim of the present study was to evaluate the influence of mildronate on the expression of proteins that are involved in the differentiation and survival of the nigrostriatal dopaminergic neurons in the rat model of Parkinson's disease (PD). The following biomarkers were used: heat shock protein 70 (Hsp70, a molecular chaperone), glial cell line-derived nerve growth factor (GDNF, a growth factor promoting neuronal differentiation, regeneration, and survival), and neural cell adhesion molecule (NCAM). MATERIAL AND METHODS PD was modeled by 6-hydroxydopamine (6-OHDA) unilateral intrastriatal injection in rats. Mildronate was administered at doses of 10, 20, and 50 mg/kg for 2 weeks intraperitoneally before 6-OHDA injection. Rat brains were dissected on day 28 after discontinuation of mildronate injections. The expression of biomarkers was assessed immunohistochemically and by western blot assay. RESULTS 6-OHDA decreased the expression of Hsp70 and GDNF in the lesioned striatum and substantia nigra, whereas in mildronate-pretreated (20 and 50 mg/kg) rats, the expression of Hsp70 and GDNF was close to the control group values. NCAM expression also was decreased by 6-OHDA in the striatum and it was totally protected by mildronate at a dose of 50 mg/kg. In contrast, in the substantia nigra, 6-OHDA increased the expression of NCAM, while mildronate pretreatment (20 and 50 mg/kg) reversed the 6-OHDA-induced overexpression of NCAM close to the control values. CONCLUSION The obtained data showed that mildronate was capable to regulate the expression of proteins that play a role in the homeostasis of neuro-glial processes.

• Publication year

  2011

• Venue

  Medicina

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3390/MEDICINA47100079PMID 22186119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Milestones in Parkinson's disease therapeutics

  2011cited by this paper
• Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.

  2011cited by this paper
• europrotective properties of mildronate , a mitochondria-targeted mall molecule

  2010cited by this paper
• Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

  2010cited by this paper
• The HSP70 Molecular Chaperone Is Not Beneficial in a Mouse Model of α-synucleinopathy

  2010cited by this paper
• Chaperone-mediated autophagy markers in Parkinson disease brains.

  2010cited by this paper
• Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats.

  2010cited by this paper
• Use of growth factors for the treatment of Parkinson’s disease

  2010cited by this paper
• Involvement of NCAM in the effects of GDNF on the neurite outgrowth in the dopamine neurons.

  2008cited by this paper
• Mitochondria as the target for mildronate's protective effects in azidothymidine (AZT)‐induced toxicity of isolated rat liver mitochondria

  2008cited by this paper
• In vivo synaptic plasticity in the dentate gyrus of mice deficient in the neural cell adhesion molecule NCAM or its polysialic acid

  2006cited by this paper
• Are heat shock proteins therapeutic target for Parkinson's disease?

  2006cited by this paper
• Hsp70 chaperones: Cellular functions and molecular mechanism

  2005cited by this paper
• Molecular pathophysiology of Parkinson's disease.

  2005cited by this paper
• Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells.

  2005influential reference
• Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons

  2004cited by this paper
• Factors promoting survival of mesencephalic dopaminergic neurons

  2004cited by this paper
• Hsp70 Reduces α-Synuclein Aggregation and Toxicity*

  2004cited by this paper
• Chaperones, protein aggregation, and brain protection from hypoxic/ischemic injury

  2004cited by this paper
• Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity.

  2004cited by this paper
• Molecular Pathways of Neurodegeneration in Parkinson's Disease

  2003cited by this paper
• Neurological diseases: Targeting programmed cell death in neurodegenerative diseases

  2003cited by this paper
• Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease.

  2003cited by this paper
• Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.

  2002cited by this paper
• Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease

  2001cited by this paper
• PSA‐NCAM distinguishes reactive astrocytes in 6‐OHDA‐lesioned substantia nigra from those in the striatal terminal fields

  2000cited by this paper

• Region-specific neuroprotective effects of meldonium pretreatment in two models of sepsis-associated encephalopathy

  2025cites this paper
• Effects of meldonium on the behavior of rats in a model of lipopolysaccharide-induced systemic inflammation

  2025cites this paper
• Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect model

  2024cites this paper
• Meldonium, as a potential neuroprotective agent, promotes neuronal survival by protecting mitochondria in cerebral ischemia–reperfusion injury

  2024cites this paper
• Protection of Testis against Lipopolysaccharide-Induced Toxicity: Mildronate-Induced L-Carnitine Depletion as a Modulator of Gut Microbiome Composition and Gastrointestinal Inflammation

  2023cites this paper
• Lipidomics Provides New Insight into Pathogenesis and Therapeutic Targets of the Ischemia—Reperfusion Injury

  2021cites this paper
• Neuroprotective effects of mildronate in a rat model of traumatic brain injury.

  2019cites this paper
• Meldonium improves Huntington’s disease mitochondrial dysfunction by restoring peroxisome proliferator‐activated receptor γ coactivator 1α expression

  2018cites this paper
• Story behind meldonium–from pharmacology to performance enhancement: a narrative review

  2016cites this paper
• Carnitine congener mildronate protects against stress- and haloperidol-induced impairment in memory and brain protein expression in rats.

  2014cites this paper
• Mildronate improves cognition and reduces amyloid‐β pathology in transgenic Alzheimer's disease mice

  2014cites this paper
• Mildronate enhances learning/memory and changes hippocampal protein expression in trained rats.

  2013cites this paper
• Mildronate and its neuroregulatory mechanisms: targeting the mitochondria, neuroinflammation, and protein expression.

  2013cites this paper
• Efficacy and Safety of Mildronate for Acute Ischemic Stroke: A Randomized, Double-Blind, Active-Controlled Phase II Multicenter Trial

  2013cites this paper
• Search for stroke-protecting agents in endothelin-1-induced ischemic stroke model in rats.

  2012cites this paper